ARCT Arcturus Therapeutics

SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Alcobra Ltd.

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alcobra Ltd. (“Alcobra” or the “Company”) (Nasdaq: ADHD). Investors who purchased or otherwise acquired shares between August 13, 2015 and January 17, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 18, 2017 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that during Class Period, Alcobra made false and/or misleading statements and/or failed to disclose that: the results of Alcobra’s first Phase III study in October 2014 revealed no statistically significant benefit derived from its primary drug candidate in development, metadoxine extended release (“MDX”); that given that the composition of MDX was unaltered from the first Phase III study, there was no basis to expect results of the second trial to be any different; that removing extreme placebo response patients from the analysis of the second Phase III trial did not boost the MDX trial results as Alcobra anticipated; and that Alcobra attributed all improvements in subjects taking MDX in the second Phase III trial to the effects of the drug, while disregarding any spontaneous improvements by placebo patients. On January 17, 2017, Alcobra revealed that MDX was unsuccessful in reaching its primary endpoint during a Phase 3 trial. When this news was released to the public, the stock price of Alcobra fell, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
28/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc: 1 director

A director at Arcturus Therapeutics Holdings Inc sold 50,000 shares at 32.030USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

 PRESS RELEASE

Arcturus Therapeutics to Present at Upcoming Investor and Scientific C...

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: TIDES: Oligonucleotide and Peptide Therapeutics scientific conference PresentationDa...

 PRESS RELEASE

Arcturus Therapeutics Announces Preclinical Publication of its COVID-1...

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on track, initial data readout expected Q4 2020 SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant ...

 PRESS RELEASE

Arcturus Therapeutics Executes Definitive Supply Agreement with the Is...

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply C...

 PRESS RELEASE

Arcturus Therapeutics Announces that it has Initiated Dosing of its CO...

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respirat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch